Catherine Stehman-Breen joined Chroma Medicine as Chief Executive Officer in 2021 and has 20 years of experience in drug development. Before joining Chroma, she was Chief development Officer of Obsidian Therapeutics and previously as entrepreneur-in-residence at Atlas Ventures, serving as Chief Medical Officer of Dyne Therapeutics and Disarm Therapeutics. Prior to that, she was Chief Medical Officer of Sarepta Therapeutics; Vice President, Clinical Development and Regulatory Affairs at Regeneron Pharmaceuticals and Vice President, Global Development at Amgen, leading the neuroscience, nephrology and bone therapeutic areas. Catherine earned her M.D. from the University of Chicago. She conducted her residency and fellowship training at the University of Washington, where she also received a Master of Science degree in Epidemiology. Catherine spent six years as a faculty member in the Division of Nephrology at the University of Washington. She has authored more than 100 scientific articles and abstracts